RhumbLine Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $6.51M | Buy |
|
|||||
|
2025
Q2 | $7.14M | Buy |
|
|||||
|
2025
Q1 | $7.53M | Sell |
|
|||||
|
2024
Q4 | $6.52M | Buy |
|
|||||
|
2024
Q3 | $6.19M | Sell |
|
|||||
|
2024
Q2 | $5.02M | Buy |
|
|||||
|
2024
Q1 | $4.99M | Buy |
|
|||||
|
2023
Q4 | $4.86M | Sell |
|
|||||
|
2023
Q3 | $3.42M | Buy |
|
|||||
|
2023
Q2 | $3.86M | Buy |
|
|||||
|
2023
Q1 | $4.66M | Buy |
|
|||||
|
2022
Q4 | $4.92M | Buy |
|
|||||
|
2022
Q3 | $3.31M | Buy |
|
|||||
|
2022
Q2 | $777K | Sell |
|
|||||
|
2022
Q1 | $1.06M | Sell |
|
|||||
|
2021
Q4 | $1M | Sell |
|
|||||
|
2021
Q3 | $793K | Buy |
|
|||||
|
2021
Q2 | $847K | Buy |
|
|||||
|
2021
Q1 | $551K | Sell |
|
|||||
|
2020
Q4 | $422K | Buy |
|
|||||
|
2020
Q3 | $354K | Sell |
|
|||||
|
2020
Q2 | $628K | Buy |
|
|||||
|
2020
Q1 | $486K | Buy |
|
|||||
|
2019
Q4 | $473K | Buy |
|
|||||
|
2019
Q3 | $666K | Sell |
|
|||||
|
2019
Q2 | $485K | Buy |
|
|||||
|
2019
Q1 | $629K | Sell |
|
|||||
|
2018
Q4 | $243K | Buy |
|
|||||
|
2018
Q3 | $319K | Sell |
|
|||||
|
2018
Q2 | $283K | Buy |
|
|||||
|
2018
Q1 | $161K | Buy |
|
|||||
|
2017
Q4 | $244K | Sell |
|
|||||
|
2017
Q3 | $194K | Buy |
|
|||||
|
2017
Q2 | $209K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $90K | Buy |
|
|||||
|
2015
Q4 | $184K | Buy |
|
|||||
|
2015
Q3 | $206K | Buy |
|
|||||
|
2015
Q2 | $267K | Buy |
|